CClinicalTrials.gg
CompletedNCT03299582Updated Oct 3, 2017

PREventing CHemotherapy Induced Neuropathy (PreChIN)

An interventional study of Hypothermia and Cryocompression in Chemotherapy-induced Peripheral Neuropathy (CIPN), sponsored by National University Hospital, Singapore. Completed. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-03.

Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
89
Allocation
Non-randomized
Ages
21 Years to 80 Years
Sex
All
01

Study summary

The project is designed to study the use of localized hypothermia alone, or with compression to the limbs during chemotherapy infusion for the prevention of chemotherapy induced peripheral neuropathy (CIPN). As a pilot study, safety, tolerability and early clinical activity will be studied. The study will be conducted on healthy volunteers and cancer patients receiving taxane chemotherapy.

Read the detailed description

Localized limb hypothermia during chemotherapeutic infusion may prevent a common side effect of chemotherapy: chemotherapy-induced peripheral neuropathy (CIPN). There are no reliable methods for the prevention or the treatment of CIPN. On the basis of the dose-related pathophysiology of CIPN, the investigators hypothesize that reducing the delivery of the toxic chemotherapeutic agents to the peripheral nerves by reducing blood flow through hypothermia may reduce the occurrence of CIPN. The proposed potential treatment method would aim to reduce the development of CIPN. This project comprises of a healthy subject trial to investigate the best tolerated temperature which will be used in cancer subject trial to investigate the safety and tolerability of hypothermia or cryocompression (hypothermia with pressure) in the prevention of CIPN in cancer subjects undergoing taxane-based chemotherapy.

02

Conditions studied

  • Chemotherapy-induced Peripheral Neuropathy (CIPN)

Keywords

  • paclitaxel
  • neuropathy
  • hypothermia
  • cryocompression
03

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The inclusion criterion for the healthy subjects

  • Age 21-80 years
  • Signed informed consent from patient
  • No history of neuropathy
  • ECOG 0
  • No history of hospitalization in the past 6 months

The inclusion criteria for the cancer patients undergoing taxane-based chemotherapy

  • Age 21- 80 years.
  • Signed informed consent from patient or legal representative.
  • Scheduled to receive taxane-based chemotherapy

The exclusion criteria for both healthy subjects and cancer patients

  • Open skin wound or ulcers of the limbs
  • A score of more than 5 in the Total Neuropathy Score (TNS) at baseline (Not applicable for healthy subjects)
  • History of Raynaud's phenomenon, peripheral vascular disease, or poorly controlled diabetes
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Healthy subjects (Hypothermia)

    To investigate the safety and tolerability of limb hypothermia in subjects without cancer

    Device: Hypothermia

  • Experimental
    Healthy subjects (Cryocompresion)

    To investigate the safety and tolerability of cryocompression in subjects without cancer

    Device: Cryocompression

  • Experimental
    Cancer subjects (Hypothermia)

    To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.

    Device: Hypothermia

  • Experimental
    Cancer subjects (Cryocompresion)

    To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.

    Device: Cryocompression

Interventions

  • DeviceHypothermia

    Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.

  • DeviceCryocompression

    Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.

05

What researchers measure

Primary outcomes

  1. Number of healthy subjects with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression

    Time frame: From the start of assessment until study completion, an average of 3 years

  2. Number of cancer patients with treatment-related intolerance as assessed by CTCAE v4.0 and tolerability scales undergoing limb hypothermia or cryocompression

    Time frame: From the start of assessment until study completion, an average of 3 years

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Tomchuk D, Rubley MD, Holcomb WR, Guadagnoli M, Tarno JM. The magnitude of tissue cooling during cryotherapy with varied types of compression. J Athl Train. 2010 May-Jun;45(3):230-7. doi: 10.4085/1062-6050-45.3.230. PubMed 20446835 ↗
  • Murgier J, Cassard X. Cryotherapy with dynamic intermittent compression for analgesia after anterior cruciate ligament reconstruction. Preliminary study. Orthop Traumatol Surg Res. 2014 May;100(3):309-12. doi: 10.1016/j.otsr.2013.12.019. Epub 2014 Mar 25. PubMed 24679367 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03299582
Lead sponsor
National University Hospital, Singapore
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
Jun 13, 2013
Primary completion
Nov 3, 2016
Completion
Feb 15, 2017
Last update
Oct 3, 2017

Study contacts

Amanda Chan
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion